The effect of long-term immunosuppressive therapy on gastrointestinal symptoms after kidney transplantation

Bulbuloglu S., Gunes H., SARITAŞ S.

TRANSPLANT IMMUNOLOGY, cilt.70, 2022 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 70
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.trim.2021.101515
  • Dergi Adı: TRANSPLANT IMMUNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Anahtar Kelimeler: Gastrointestinal symptoms, Immunosuppressive agents, Immunosuppressive therapy, Long-term immunosuppression, Kidney transplantation, Renal recipients, RENAL-TRANSPLANTATION, UNITED-STATES, ADHERENCE, COMPLICATIONS, REJECTION, DIARRHEA, RELIABILITY, DISORDERS, SURVIVAL, VALIDITY
  • İnönü Üniversitesi Adresli: Evet

Özet

Objective: We examined the relationship between compliance with long-term immunosuppressive therapy after kidney transplantation and gastrointestinal (GI) symptoms in patients discharged from hospitals in this study. Method: Our study was conducted as a descriptive study with the participation of 114 kidney transplant recipients discharged from the organ transplant center of a training and research hospital. Personal Information Form, Immunosuppressive Therapy Compliance Scale and Gastrointestinal Symptom Rating Scale were used in data collection. The data analysis was performed with IBM Statistical Package for the Social Sciences (SPSS) Statistics 25. Results: According to the findings, 47.4% of kidney transplant patients were between the ages of 46 and 64, and 80.7% of them were male. 41.2% of kidney recipients used immunosuppressive agents between 91 days and 6 months. Compliance with immunosuppressive therapy was similar in all age groups. It was determined that the recipients between the ages of 18 and 30 experienced GI symptoms the most. In terms of the predictors of GI symptoms, it was determined that mycophenolate mofetil (MMF) was effective in the development of reflux and diarrhoea, cyclosporine in the development of diarrhoea and constipation, and tacrolimus in the development of indigestion, which are (p < 0.05). Conclusion: For kidney recipients to have high compliance with immunosuppressive therapy, it is of great importance that they are able to cope with GI symptoms. Our study showed that GI symptoms increase in direct proportion as the duration of immunosuppressive therapy is prolonged and the level of compliance increases. GI symptoms of kidney transplant patients should be recognized, and recipients should be helped to manage those problems.